The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
Author:
Affiliation:
1. Xcenda, Palm Harbor, FL, USA;
2. Biogen, Weston, MA, USA
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1258366
Reference38 articles.
1. US National Library of Medicine. Multiple Sclerosis (MS). http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed August 14, 2014
2. National Multiple Sclerosis Society. Types of MS. http://www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed August 14, 2014
3. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates
4. Economic Burden of Multiple Sclerosis
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16
2. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom;Journal of Medical Economics;2023-12-26
3. Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States;Neurology and Therapy;2023-03-31
4. Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review;Acta Medica Bulgarica;2022-12-01
5. Cost-Utility and Cost-Effectiveness Analysis of disease-modifying drugs of Relapsing-Remitting Multiple Sclerosis: A Systematic Review;2022-08-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3